Patient-derived xenografts and matched cell lines identify pharmacogenomic vulnerabilities in colorectal cancer

Lazzari, L.; Corti, G.; Picco, G.; Isella, C.; Montone, M.; Arcella, P.; Durinikova, E.; Zanella, E.R.; Novara, L.; Barbosa, F.; Cassingena, A.; Cancelliere, C.; Medico, E.; Sartore-Bianchi, A.; Siena, S.; Garnett, M.J.; Bertotti, A.; Trusolino, L.; Di Nicolantonio, F.; Linnebacher, M.; Bardelli, A.; Arena, S.

doi:10.1158/1078-0432.CCR-18-3440

Patient-derived xenograft (PDX) models accurately recapitulate the tumor of origin in terms of histopathology, genomic landscape, and therapeutic response, but some limitations due to costs associated with their maintenance and restricted amenability for large-scale screenings still exist. To overcome these issues, we established a platform of 2D cell lines (xeno-cell lines, XLs), derived from PDXs of colorectal cancer (CRC) with matched patient germline gDNA available.

Patient-derived xenografts and matched cell lines identify pharmacogenomic vulnerabilities in colorectal cancer / L. Lazzari, G. Corti, G. Picco, C. Isella, M. Montone, P. Arcella, E. Durinikova, E.R. Zanella, L. Novara, F. Barbosa, A. Cassingena, C. Cancelliere, E. Medico, A. Sartore-Bianchi, S. Siena, M.J. Garnett, A. Bertotti, L. Trusolino, F. Di Nicolantonio, M. Linnebacher, A. Bardelli, S. Arena. - In: CLINICAL CANCER RESEARCH. - ISSN 1557-3265. - 25:20(2019 Aug 02), pp. 6243-6259. [10.1158/1078-0432.CCR-18-3440]